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Abstract
Background: Malaria causes a reduction in haemoglobin that is compounded by primaquine, particularly in
patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. The aim of this study was to determine the
relative contributions to red cell loss of malaria and primaquine in patients with uncomplicated Plasmodium vivax.
Methods: A systematic review identified P. vivax efficacy studies of chloroquine with or without primaquine
published between January 2000 and March 2017. Individual patient data were pooled using standardised
methodology, and the haematological response versus time was quantified using a multivariable linear mixed
effects model with non-linear terms for time. Mean differences in haemoglobin between treatment groups at day
of nadir and day 42 were estimated from this model.
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Results: In total, 3421 patients from 29 studies were included: 1692 (49.5%) with normal G6PD status, 1701 (49.7%)
with unknown status and 28 (0.8%) deficient or borderline individuals. Of 1975 patients treated with chloroquine
alone, the mean haemoglobin fell from 12.22 g/dL [95% CI 11.93, 12.50] on day 0 to a nadir of 11.64 g/dL [11.36,
11.93] on day 2, before rising to 12.88 g/dL [12.60, 13.17] on day 42. In comparison to chloroquine alone, the mean
haemoglobin in 1446 patients treated with chloroquine plus primaquine was − 0.13 g/dL [− 0.27, 0.01] lower at day
of nadir (p = 0.072), but 0.49 g/dL [0.28, 0.69] higher by day 42 (p < 0.001). On day 42, patients with recurrent
parasitaemia had a mean haemoglobin concentration − 0.72 g/dL [− 0.90, − 0.54] lower than patients without
recurrence (p < 0.001). Seven days after starting primaquine, G6PD normal patients had a 0.3% (1/389) risk
of clinically significant haemolysis (fall in haemoglobin > 25% to < 7 g/dL) and a 1% (4/389) risk of a fall in
haemoglobin > 5 g/dL.
Conclusions: Primaquine has the potential to reduce malaria-related anaemia at day 42 and beyond by
preventing recurrent parasitaemia. Its widespread implementation will require accurate diagnosis of G6PD
deficiency to reduce the risk of drug-induced haemolysis in vulnerable individuals.
Trial registration: This trial was registered with PROSPERO: CRD42016053312. The date of the first registration
was 23 December 2016.
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Background
Outside of sub-Saharan Africa, Plasmodium vivax is a
significant cause of morbidity and mortality in malaria-
endemic regions [1–3], resulting in approximately 10
million cases of malaria each year [4]. Anaemia is a com-
mon manifestation of vivax malaria, with parasitaemia
causing loss of infected and uninfected red blood cells
(RBC), as well as reduced RBC production due to dyser-
ythropoiesis [5]. The haematological burden of the dis-
ease is compounded by P. vivax’s ability to form
dormant liver stages (hypnozoites) that can reactivate
weeks to months after the initial infection, causing mul-
tiple relapses [5, 6]. Radical cure of both the erythrocytic
and hypnozoite stages of the parasite can prevent recur-
rent symptomatic P. vivax infections and thus reduce
the cumulative risk of anaemia [7].
Primaquine (PQ), an 8-aminoquinoline compound in
use for over 60 years, remains the only widely available
drug with activity against hypnozoites, although another
8-aminoquinoline, tafenoquine, was recently licenced by
the FDA [8]. 8-Aminoquinolines can cause severe haem-
olysis in individuals with glucose-6-phosphate dehydro-
genase deficiency (G6PDd), an inherited enzymopathy
caused by genetic polymorphisms in the X chromosome.
The risk of drug-induced haemolysis relates to the dose
of PQ and an individual’s genetic polymorphism [9–11].
In general, routine testing for G6PDd is unavailable in
most endemic areas and concerns regarding severe
haemolysis are a major barrier to widespread clinical use
of PQ [12, 13].
The relative contributions of malaria itself and PQ
treatment to haemoglobin reductions in patients with
vivax malaria are poorly defined. This study aimed to de-
termine the degree of haemoglobin reduction following
chloroquine (CQ), the standard blood schizontocidal
treatment of vivax malaria [14] and to quantify any add-
itional reduction relating to haemolysis from PQ co-
administration.
Methods
Search strategy and selection criteria
A systematic search was undertaken in MEDLINE, Web
of Science, Embase and the Cochrane Database of Sys-
tematic Reviews according to the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines (Additional file 1: Checklist S1).
Prospective therapeutic efficacy trials of treatment of un-
complicated vivax malaria with a minimum of 28 days
follow-up, published between 1 January 2000 and 22
March 2017, in any language were identified (Add-
itional file 1: Box S1) [15]. Investigators of eligible stud-
ies were invited to participate in an individual patient
data meta-analysis and contribute data from similar un-
published studies.
Studies were included in the analysis if they enrolled
patients with P. vivax monoinfection treated with CQ,
alone or with PQ, and recorded haemoglobin (Hb) or
haematocrit at baseline. Studies of pregnant women and
treatment with adjunctive antimalarials were excluded.
Individual patient data were shared on the WorldWide
Antimalarial Resistance Network (WWARN) repository,
anonymised and standardised [16]. The review protocol
was registered in the International Prospective Register
of Systematic Reviews (PROSPERO: CRD42016053312).
Procedures
The doses of CQ and PQ were calculated from the num-
ber of tablets given to each patient, or the study protocol
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if tablet numbers were unavailable. Patient records were
excluded if CQ was not administered; PQ was adminis-
tered after day 0; no Hb or haematocrit was recorded on
day 0; adjunctive antimalarials were administered; P.
vivax was not present at day 0; information on the dose
given, parasitaemia, age or gender was unavailable; the
CQ treatment course was incomplete; mixed infections
were present at day 0; or PQ was dosed intermittently.
G6PD status was recorded when reported, and defi-
ciency was diagnosed by either a qualitative assay
(fluorescent spot test or the CareStart® rapid diagnos-
tic test) or a quantitative assay (spectrophotometry).
G6PDd was defined as an enzyme activity less than
30% (Additional file 1: Table S1).
Study sites were categorised into regions of long or
short P. vivax relapse periodicity [17], with regions of
short relapse periodicity considered to have a median
time to relapse of ≤ 47 days. To avoid confounding from
early treatment failure, recurrence was defined as vivax
parasitaemia between days 7 and 42. Daily PQ mg/kg
dose was defined as low dose if < 0.5 mg/kg/day and high
dose if ≥ 0.5 mg/kg/day.
When only the haematocrit was available, it was con-
verted to Hb according to the equation [18]:
Hb g=dLð Þ ¼ haematocrit %ð Þ  5:62ð Þ=2:6
Where multiple Hb measurements were recorded on a
single day, the minimum value was used.
Statistical analysis
Linear mixed effects modelling of the Hb versus time
profiles (described below) was used to derive the pri-
mary endpoint of the mean drop in Hb from day 0
(baseline) to the day of the nadir and the secondary end-
points of the mean change in Hb from baseline to day 7
and day 42. In addition, two safety outcomes identified
patients at risk of poor clinical outcome: a Hb fall of >
25% from a baseline of ≥ 7 g/dL to a Hb < 7 g/dL (de-
fined as a clinically significant fall) and an absolute fall
in Hb of > 5 g/dL. The safety outcomes were assessed at
day 2 or 3 (day 2/3), day 7 ± 2 days (day 7) and day 28 ±
3 days (day 28).
Statistical analyses were done using Stata v15 (Stata-
Corp) and R version 3.4.0 (R Foundation for Statistical
Computing), according to an a priori statistical analysis
plan [19]. The mean Hb-time response following treat-
ment was estimated using a linear mixed effects model
[20] with non-linear terms, derived by fractional polyno-
mial regression [21, 22]; with fixed effects for age, gen-
der, baseline parasitaemia, total CQ dose (mg/kg),
relapse periodicity and PQ use; and with random effects
fitted to the terms for time according to an individual
within each study site. The interaction between PQ use
and time was included in order to capture the different
time course of Hb responses following the two regimens
CQ or CQ+PQ. In the subgroup of patients treated with
PQ, the effect of the daily mg/kg PQ dose on Hb re-
sponse was estimated using a similar linear mixed effects
model. The primary analysis was repeated in subgroups
of patients with documented normal G6PD status and
unknown G6PD status and by gender. Additional factors
associated with the change in haemoglobin between day
0 and day of nadir were assessed using a linear regres-
sion model with shared frailty for the study site.
A sensitivity analysis was undertaken to assess poten-
tial selection bias, removing one study at a time and cal-
culating the coefficient of variation in the estimates of
the primary analysis. Baseline characteristics of included
studies were also compared to studies that were targeted
but not available for inclusion.
The effect of delayed parasite clearance (defined as
persistence of parasitaemia until day 2 or later) on Hb at
day of nadir and day 42 and the effect of recurrence be-
tween days 7 and 42 on Hb at day 42 were assessed
using separate linear mixed effects models similar to the
model above with the interaction between PQ and time
replaced by interactions between delayed parasite clear-
ance or recurrence and time. In the model of recurrence
between days 7 and 42, patients with early treatment
failure, late clinical failure prior to day 7 or persistent
parasitaemia between days 4 and 6 were excluded from
the analysis.
A descriptive table of safety outcomes was presented
to provide commonly reported parameters of the Hb re-
sponse in published clinical trials; the numbers of pa-
tients available for these summary statistics varied
according to the time point presented. There were insuf-
ficient numbers of patients experiencing either of the
safety outcomes to conduct multivariable analyses of the
haemolytic risk attributable to PQ.
Results
Between 1 January 2000 and 22 March 2017, there were
168 published P. vivax clinical trials of which 134
(79.8%) included patients treated with CQ and 56
(33.3%) provided information on Hb concentration or
haematocrit. Individual patient data were available for
5150 (46.9%) patients from 25 of these studies plus 1892
additional patients (1780 from four unpublished studies
and 112 from published studies). Of the 7042 patients
with available data, 2813 (39.9%) were not treated with
CQ, 306 (4.3%) were treated with PQ after day 0 and
502 (7.1%) were excluded for other reasons (Fig. 1 and
Additional file 1: Table S1–S3). Of the remaining 3421
patients, 1975 (57.7%) were treated with CQ alone and
1446 (42.3%) with CQ+PQ [23–51].
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Patients were followed for 28 days in 14 studies (n =
1841), 29 to 42 days in seven studies (n = 388) and more
than 42 days in eight studies (n = 1192). In total, G6PD
status was normal in 1692 (49.5%) patients, deficient or
borderline deficient in 28 (0.8%) and unknown in 1701
(49.7%) (Additional file 1: Table S4). All G6PD-deficient
and borderline patients were identified prior to treat-
ment and were administered CQ alone, except for one
deficient patient who was treated with CQ+PQ and was
diagnosed post hoc. Target PQ regimens are described
in Additional file 1: Table S5.
The majority of patients were male (64.6%, 2211/3421).
The median age of patients was 19 years (inter-quartile
range (IQR) 9–32), with 1314 (38.4%) patients younger
than 15 years (Table 1). Most of the patients were enrolled
from the Asia-Pacific region (2247, 65.7%), with 598
(17.5%) enrolled from The Americas and 576 (16.8%) from
the Horn of Africa (Additional file 1: Figure S1). Com-
pared to patients treated with CQ, those treated with
CQ+PQ tended to be older, have lower baseline parasitae-
mias and be more likely to come from areas of short re-
lapse periodicity (Table 1). Baseline characteristics of
G6PD normal patients and patients with unknown G6PD
status are described separately in Additional file 1:
Table S6–S7. Compared to the studies that were tar-
geted but not included, included studies were con-
ducted more recently, enrolled younger populations
and included more equal proportions of male and fe-
male patients (Additional file 1: Table S8).
Baseline haemoglobin
The mean Hb at baseline was 12.2 g/dL (SD 2.1) in
patients receiving CQ and 12.7 g/dL (SD 2.1) in pa-
tients receiving CQ+PQ. Overall, 11.3% (385/3421) of
patients were anaemic at baseline (Hb < 10 g/dL), in-
cluding 13.1% (259/1975) in those subsequently
treated with CQ and 8.7% (126/1446) in those treated
with CQ+PQ. Severe anaemia (Hb < 7 g/dL) was present
in 0.8% (26/3421) of patients. The odds of anaemia at
baseline was greater in females (adjusted odds ratio
(AOR) = 1.34 [95% CI 1.05, 1.71]) and patients who were
younger than 5 years (AOR = 10.37 [6.09, 17.67]), G6PD
deficient (AOR = 2.88 [1.14, 7.32]) and enrolled in regions
of short relapse periodicity (AOR = 1.94 [1.01, 3.71])
(Additional file 1: Table S9).
Fig. 1 Study flowchart
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Haemoglobin-time profile
The Hb profile between baseline and day 42 was mod-
elled from 9684 Hb measurements in 1975 patients
treated with CQ alone and 6029 Hb measurements in
1446 patients treated with CQ+PQ. Patients treated with
CQ alone had a median [IQR] of 7 [5-9] Hb measure-
ments, and patients treated with CQ+PQ had a median
[IQR] of 9 [3-10] Hb measurements.
Haemoglobin profile following treatment with
chloroquine alone
In patients treated with CQ alone, the mean Hb fell
from baseline to a nadir on day 2, with a fall of 0.58
g/dL from a mean of 12.22 g/dL [95% CI 11.93,
12.50] to 11.64 g/dL [11.36, 11.93] (Fig. 2). Following
the nadir, the Hb rose thereafter. By day 42, the mean
Hb was 12.88 g/dL [12.60, 13.17], 0.67 g/dL above
baseline.
The magnitude and direction of the change in Hb
from baseline to day 2 or day 7 varied with the baseline
Hb, with a high baseline Hb correlated with a large fall
in Hb (Figs. 3 and 4 and Additional file 1: Figure S2).
Only 32.8% (136/415) of patients with a baseline Hb <
11.5 g/dL fell below their baseline Hb during the first 7
days compared with 70.9% (565/797) of those with a
baseline Hb ≥ 11.5 g/dL (Fig. 2).
Table 1 Demographics, baseline characteristics and baseline haemoglobin measurements
Chloroquine alone Chloroquine plus primaquine Overall
Number
(%)*
Mean Hb
(SD)
Range Number
(%)*
Mean Hb
(SD)
Range Number
(%)*
Mean Hb
(SD)
Range
Overall 1975 (100) 12.2 (2.1) 6.0 to 18.7 1446 (100) 12.7 (2.1) 4.0 to 19.0 3421 (100) 12.4 (2.1) 4.0 to 19.0
Parasitaemia, parasites
per uL; median (IQR)
3400 (1261,
8290)
2700 (912,
7040)
3104 (1137,
8000)
Gender
Female 772 (39.1) 11.8 (1.9) 6.0 to 17.4 438 (30.3) 11.7 (1.8) 4.0 to 17.4 1210 (35.4) 11.7 (1.9) 4.0 to 17.4
Male 1203 (60.9) 12.5 (2.1) 6.6 to 18.7 1008 (69.7) 13.1 (2.1) 4.9 to 19.0 2211 (64.6) 12.8 (2.1) 4.9 to 19.0
Age category, years
< 5 225 (11.4) 10.7 (2.0) 6.0 to 16.6 72 (5.0) 10.3 (1.8) 4.9 to 14.1 297 (8.7) 10.6 (2.0) 4.9 to 16.6
5 to < 15 691 (35.0) 11.6 (1.8) 6.6 to 17.4 326 (22.5) 11.5 (1.6) 5.5 to 16.3 1017 (29.7) 11.6 (1.8) 5.5 to 17.4
≥ 15 1059 (53.6) 13.0 (1.9) 6.2 to 18.7 1048 (72.5) 13.2 (2.0) 4.0 to 19.0 2107 (61.6) 13.1 (2.0) 4.0 to 19.0
Weight category, kg
5 to < 15 195 (9.9) 10.4 (1.9) 6.0 to 16.3 83 (5.7) 10.3 (1.6) 5.2 to 13.4 278 (8.1) 10.4 (1.8) 5.2 to 16.3
15 to < 25 440 (22.3) 11.5 (1.9) 6.9 to 16.6 172 (11.9) 11.1 (1.6) 4.9 to 15.9 612 (17.9) 11.4 (1.8) 4.9 to 16.6
25 to < 35 182 (9.2) 11.7 (1.6) 6.6 to 16.2 94 (6.5) 11.7 (1.6) 7.5 to 15.1 276 (8.1) 11.7 (1.6) 6.6 to 16.2
35 to < 45 196 (9.9) 12.1 (1.9) 6.5 to 17.4 153 (10.6) 12.1 (1.9) 5.8 to 17.1 349 (10.2) 12.1 (1.9) 5.8 to 17.4
45 to < 55 404 (20.5) 12.9 (1.9) 6.2 to 18.7 338 (23.4) 12.9 (1.9) 5.4 to 18.1 742 (21.7) 12.9 (1.9) 5.4 to 18.7
55 to < 80 484 (24.5) 13.1 (1.9) 7.0 to 18.1 508 (35.1) 13.6 (1.9) 4.0 to 19.0 992 (29.0) 13.3 (1.9) 4.0 to 19.0
≥ 80 74 (3.7) 13.8 (1.3) 9.9 to 16.5 98 (6.8) 14.0 (1.7) 8.2 to 17.9 172 (5.0) 13.9 (1.5) 8.2 to 17.9
G6PD status
Normal 856 (43.3) 12.4 (1.9) 6.5 to 18.1 836 (57.8) 12.8 (2.0) 5.4 to 19.0 1692 (49.5) 12.6 (2.0) 5.4 to 19.0
Borderline 3 (0.2) 13.9 (1.1) 13.1 to 15.2 0 (0) – – 3 (0.1) 13.9 (1.1) 13.1 to 15.2
Deficient 24 (1.2) 12.4 (1.8) 8.6 to 15.7 1 (0.1) 14.0 (−) 14.0 to 14.0 25 (0.7) 12.4 (1.8) 8.6 to 15.7
Not known 1092 (55.3) 12.1 (2.2) 6.0 to 18.7 609 (42.1) 12.5 (2.2) 4.0 to 18.9 1701 (49.7) 12.2 (2.2) 4.0 to 18.9
Relapse periodicity
Long 1360 (68.9) 12.3 (2.1) 6.0 to 18.1 627 (43.4) 13.4 (1.9) 4.0 to 18.9 1987 (58.1) 12.6 (2.1) 4.0 to 18.9
Short 615 (31.1) 12.1 (2.0) 6.2 to 18.7 819 (56.6) 12.2 (2.1) 4.9 to 19.0 1434 (41.9) 12.2 (2.0) 4.9 to 19.0
Geographical region
Asia-Pacific 1114 (56.4) 11.9 (1.9) 6.2 to 18.7 1133 (78.4) 12.5 (2.1) 4.9 to 19.0 2247 (65.7) 12.2 (2.0) 4.9 to 19.0
The Americas 285 (14.4) 12.5 (2.0) 7.0 to 17.4 313 (21.6) 13.5 (1.8) 4.0 to 18.9 598 (17.5) 13.0 (2.0) 4.0 to 18.9
Africa 576 (29.2) 12.7 (2.2) 6.0 to 18.1 0 (0) – – 576 (16.8) 12.7 (2.2) 6.0 to 18.1
Hb haemoglobin, SD standard deviation, IQR inter-quartile range
*Number of patients (percentage of total patients in group) unless otherwise specified
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Haemoglobin profile following treatment with
chloroquine and primaquine
The nadir Hb in patients treated with CQ+PQ occurred
on day 3, with the mean Hb rising throughout the subse-
quent follow-up (Fig. 2).
Compared to patients treated with CQ alone, those
treated with CQ+PQ had a lower Hb at nadir (mean
difference − 0.13 g/dL [95% CI − 0.27, 0.01], p = 0.072)
and day 7 (− 0.34 g/dL [− 0.46, − 0.23], p < 0.001), but
higher Hb at day 42 (mean difference 0.49 g/dL [0.28,
0.69], p < 0.001; Table 2). In a sensitivity analysis, the re-
moval of one study site at a time did not identify signifi-
cant evidence of bias related to the included studies
(Additional file 1: Table S10).
A B
C D
Fig. 2 Mean haemoglobin-time profiles for a any baseline haemoglobin, b baseline ≥ 11.5 g/dL, c baseline < 11.5 g/dL and d normal G6PD status.
Figures derived from the linear mixed effects model with fractional polynomial terms for time. Profiles for chloroquine (CQ) alone and chloroquine
plus primaquine (CQ+PQ) adjusted to the same baseline haemoglobin. Shaded regions show 95% confidence intervals. In total, 1975 patients were
treated with CQ alone and 1446 with CQ+PQ; in patients with baseline Hb ≥ 11.5 g/dL, the corresponding figures were 1277 and 1063; in patients
with baseline Hb < 11.5 g/dL, the corresponding figures were 698 and 383; and in patients with normal G6PD status, the corresponding figures were
856 and 836
A B
Fig. 3 Relationship between haemoglobin at baseline and day 7 as a fractional change and b absolute change. One thousand two hundred
twenty-two patients were treated with chloroquine (CQ) alone and 539 with chloroquine plus primaquine (CQ+PQ). The open circle represents
the single patient with a clinically significant fall > 25% to < 7 g/dL at day 7 (female patient with normal G6PD status). The dashed orange line
represents a fractional fall of 25%. The baseline Hb correlated negatively with the fractional change in Hb at day 7 (r = − 0.521 [95% CI − 0.554 to
− 0.486], p < 0.0001)
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Of the 1446 patients treated with PQ, 38.2% (553)
were treated with a high daily dose and 61.8% (893) with
a low daily dose. There was no significant difference in
mean Hb between patients treated with a high or low
daily PQ dose, either at day 3 (mean difference 0.14 g/dL
[− 0.05, 0.33], p = 0.161) or day 7 (mean difference 0.18
g/dL [− 0.11, 0.46], p = 0.227).
In subgroup analyses, the mean Hb at the day of nadir
was significantly lower in patients treated with CQ+PQ
than in those treated with CQ in females (mean differ-
ence − 0.25 g/dL [− 0.43, − 0.07], p = 0.007), and patients
with unknown G6PD status (mean difference – 0.65 g/
dL [− 0.82, − 0.47], p < 0.001), but there was no signifi-
cant difference between treatment groups in males or
patients known to be G6PD normal (Table 2). In G6PD
normal patients, the following factors were associated
with a greater reduction in Hb at day of nadir: younger
age, higher baseline Hb, higher baseline parasitaemia,
female gender and short relapse periodicity
(Additional file 1: Table S11). By day 42, the mean Hb
was higher following CQ+PQ compared to CQ alone for
females (mean difference 0.45 g/dL [0.18, 0.72], p =
0.001), males (0.62 g/dL [0.29, 0.94], p < 0.001) and pa-
tients with normal G6PD status (0.89 g/dL [0.53, 1.26],
p < 0.001) (Fig. 2 and Additional file 1: Figure S3). None
of the patients with unknown G6PD status treated with
CQ+PQ had a Hb measure at day 42, precluding day 42
comparison between treatment groups in this subgroup.
Overall, 17.4% (344/1975) of patients treated with CQ
had recurrent parasitaemia between days 7 and 42, com-
pared to 2.0% (29/1446) of those treated with CQ+PQ.
The mean Hb at day 42 was significantly lower in
A B
Fig. 4 Fractional change in haemoglobin between baseline and day 7 following a chloroquine and b chloroquine plus primaquine. In patients
treated with chloroquine alone, 608 had normal G6PD status and 588 had unknown G6PD status. In patients treated with chloroquine plus
primaquine, 389 had normal G6PD status and 150 had unknown G6PD status. The open circle represents the single patient with a clinically
significant fall > 25% to < 7 g/dL at day 7 (female patient with normal G6PD status). The dashed orange line represents a fractional fall of 25%
Table 2 The mean difference in haemoglobin between patients treated with and without primaquine
Day of nadir Day 7 Day 42
Patient group Mean difference* (95% CI,
g/dL)
p value Mean difference* (95% CI,
g/dL)
p value Mean difference* (95% CI,
g/dL)
p value
Overall (n = 3421†) − 0.13 (− 0.27, 0.01) 0.072 − 0.34 (− 0.46, − 0.23) < 0.001 0.49 (0.28, 0.69) < 0.001
Normal G6PD status
(n = 1692)
0.05 (− 0.14, 0.24) 0.577 − 0.23 (− 0.39, − 0.07) 0.004 0.89 (0.53, 1.26) < 0.001
Unknown G6PD status
(n = 1701)
− 0.65 (− 0.82, − 0.47) < 0.001 − 0.44 (− 0.66, − 0.21) < 0.001 Not calculable‡ –
Females (n = 1210) − 0.25 (− 0.43, − 0.07) 0.007 − 0.36 (− 0.54, − 0.18) < 0.001 0.45 (0.18, 0.72) 0.001
Males (n = 2211) − 0.11 (− 0.30, 0.08) 0.241 − 0.33 (− 0.48, − 0.18) < 0.001 0.62 (0.29, 0.94) < 0.001
CI confidence interval
*The difference in the mean haemoglobin comparing patients treated with or without primaquine. A negative mean difference equates to a lower haemoglobin
when treated with chloroquine plus primaquine. Linear mixed effects models with non-linear terms for time were used to derive estimates of mean haemoglobin
at day of nadir, day 7 and day 42
†n represents the number of patients who contributed at least one follow-up haemoglobin measurement for the linear mixed effects modelling of the
haemoglobin trajectories
‡no day 42 haemoglobin measurements were available for patients treated with chloroquine plus primaquine
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patients with recurrent parasitaemia compared to those
with no recurrence (mean difference − 0.72 g/dL [− 0.90,
− 0.54], p < 0.001). The only G6PD-deficient patient
treated with CQ+PQ had a haemoglobin fall from 14 g/
dL at day 0 to 6.6 g/dL at day 14 but was not tested in
between (Additional file 1: Table S12-S13).
Effect of delayed parasite clearance on haemoglobin
profile
In total, 37.1% (1000/2698) of patients had cleared their
parasitaemia by day 1, 76.9% (2076/2698) had cleared by
day 2 and 23.1% (622/2698) had parasite clearance de-
layed until after day 2. The proportion with delayed
parasite clearance after day 2 was 17.6% (290/1646) fol-
lowing CQ and 31.6% (332/1052) following CQ+PQ.
After controlling for confounding factors including PQ
treatment, patients with delayed parasite clearance had a
significantly lower Hb at the day of nadir (mean differ-
ence − 0.26 g/dL [− 0.45, − 0.06], p = 0.010) and day 42
(mean difference − 0.23 g/dL [− 0.39, − 0.07], p = 0.004)
(Additional file 1: Figure S4).
Safety outcomes
None of the patients died. Whilst 1.1% (7/610) of pa-
tients treated with CQ and 5.7% (27/471) treated with
CQ+PQ had a fractional fall in Hb greater than 25%
from baseline at day 2/3, 94.1% (32/34) of these patients
started with a Hb greater than or equal to 11.5 g/dl. On
day 2/3, none of the 610 patients treated with CQ alone
had a clinically significant fall (fall in Hb > 25% to < 7 g/
dL) or a fall greater than 5 g/dL. Of the patients treated
with CQ+PQ, one G6PD normal male patient had a clin-
ically significant fall and six patients with G6PD un-
known status had a fall greater than 5 g/dL, one of
whom was female (Table 3 and Additional file 1: Table
S12–S13). On day 7, G6PD normal patients had a 0.3%
(1/389) risk of clinically significant haemolysis and a 1%
(4/389) risk of a fall in haemoglobin > 5 g/dL. The risks
of safety outcomes occurring at day 28 and in patients
with unknown or deficient G6PD status are presented in
Table 3, Fig. 4 and Additional file 1: Table S14. No
patients were reported to have received a blood
transfusion.
In unadjusted analyses of G6PD normal patients, the
number needed to harm to have a clinically significant
drop in Hb at day 2/3 was 334 exposures to PQ and the
corresponding number needed to harm at day 7 was 389
patients.
Discussion
This meta-analysis of data from 3421 individual patients
enrolled in 29 studies provides the most detailed evalu-
ation of the haematological consequences of vivax mal-
aria treated with CQ, with and without PQ, in over 60
years. In patients with normal G6PD status, patients
treated with PQ had no additional clinically significant
haemolysis compared to CQ alone. However, patients
treated with PQ had higher haemoglobins by day 42
(0.5 g/dL higher), a difference likely attributable in part
to a reduction in recurrent parasitaemia.
Treatment with PQ reduces the risk of vivax recur-
rences at day 42 by up to 90%, predominantly because of
its ability to prevent reactivation of dormant liver stages
[47, 49, 52, 53]. Despite this benefit, clinician concern
regarding the risk of severe haemolysis in patients with
G6PDd, coupled with a lack of reliable point of care tests
for G6PDd, has prevented the widespread uptake of PQ
radical cure in many vivax-endemic regions [12]. The
risks of severe haemolysis attributable to PQ need to be
quantified and weighed against the underlying risk of an-
aemia attributable to malaria itself. Our analysis high-
lights that in a study population where the majority of
patients were confirmed or suspected to be G6PD nor-
mal, there was minimal additional haemolysis attribut-
able to PQ beyond the fall in Hb occurring after
treatment with CQ. In our analysis, the fall in Hb was
not influenced by the daily dose of PQ administered.
Consistent with previous studies, by day 42, patients
treated with PQ had a substantially higher Hb, likely
reflecting the prevention of relapse and potential recru-
descence [49, 54].
Previous antimalarial studies have used an arbitrary fall
in Hb of > 25% as a safety outcome [55, 56]. Whilst 5.7%
treated with CQ+PQ had a fractional fall in Hb > 25% at
day 2/3, almost all of these patients had a high baseline
Hb; hence, a large fractional fall in Hb may not necessar-
ily equate to clinically relevant morbidity. We explored
two alternative clinically specific safety measures: a com-
posite measure of a fall > 25% from baseline to a Hb < 7
g/dL, and a fall in Hb > 5 g/dL. The former reflects Hb
reduction to a level associated with rising risk of mortal-
ity [6], and the latter possible substantial intravascular
haemolysis leading to an increased risk of high cell-free
Hb and acute renal failure [57]. The overall risk of these
safety outcomes at day 2/3 was approximately 15 per
1000 patients treated, substantially less than the risk of
patients having a high fractional fall in Hb.
Reassuringly in this study population, no patients with
unknown G6PD status had a clinically relevant fall in
Hb at either day 2/3 or day 7. These patients were from
Brazil, Indonesia and Vietnam, where G6PD testing is
not routinely recommended in the National guidelines.
Although these study populations may be perceived to
have a low risk of G6PDd, these areas are known to in-
clude some patients with severe G6PD variants. In the
studies included in our analysis when patients were
screened for G6PDd, normal activity was defined as an
enzyme activity greater than 30%. This approach will not
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have excluded heterozygous females with intermediate
G6PD activity and is the likely reason that the mean
nadir Hb of female patients was lower following CQ+PQ
compared to females treated with CQ alone. Import-
antly, only one female patient had a clinically relevant
fall in Hb at day 2/3 or day 7. In the G6PD normal pa-
tients, PQ treatment was associated with one additional
patient with a clinically relevant fall in Hb at day 2/3 for
every 334 patients treated; these estimates are un-
adjusted for confounding factors. Hence, whilst PQ did
not cause a significant increase in the population risk of
haemolysis in patients with proven or suspected G6PD
normal status, there remains an appreciable risk of se-
vere haemolysis in vulnerable individuals. Our study
highlights the importance of reliable and accurate point
of care testing of G6PD status prior to radical cure of P.
vivax, in conjunction with clinical or laboratory moni-
toring for haematological recovery.
The day of nadir Hb occurred on day 2 in patients
treated with CQ alone and day 3 in those treated with
CQ+PQ, and yet less than half of the clinical studies
sampled Hb on these days routinely. Future studies aim-
ing to quantify PQ-induced haemolysis should consider
reviewing patients around day 3, after completion of
blood schizontocidal treatment, at which time patients
at greatest risk of clinically harmful haemolysis could be
identified and appropriate management initiated, if
indicated.
Our analysis included patients irrespective of their
G6PD status, all of whom were judged to be suitable for
treatment with PQ. Not all studies tested patients for
G6PDd, reflecting variations in regional protocols. Pa-
tients with unknown G6PD status treated with PQ had a
lower mean Hb at nadir which may reflect unidentified
patients with G6PDd. Furthermore, even in female pa-
tients with normal G6PD status, those treated with PQ
had a lower mean Hb at nadir which may reflect inclu-
sion of heterozygous individuals with intermediate
G6PDd who would have been screened as G6PD normal
by qualitative tests. A small number of adverse safety
outcomes occurred with and without primaquine treat-
ment across all patient groups; within the first 7 days,
53% (8/15) of adverse events occurred in patients with
normal G6PD status, 47% (7/15) in those with unknown
status and 27% (4/15) in female patients.
Our study has several important limitations. Lack of
PQ randomisation led to the potential for differences be-
tween patient groups and selection bias that could not
be adjusted for. For example, no patients from Africa
were treated with PQ. Inclusion of data from only half of
the patients from the targeted clinical trials is an add-
itional limitation. Despite minor epidemiological differ-
ences between the populations of studies included and
targeted (Additional file 1: Table S8), the studies in our
analysis were undertaken in a range of populations in
vivax-endemic areas. Furthermore, the mean baseline
Hb was similar between the included and targeted stud-
ies suggesting that differences in the haematological pro-
files of these populations were unlikely to be an
important source of bias. A sensitivity analysis did not
identify significant evidence of bias related to the in-
cluded studies (Additional file 1: Table S10). Whilst it is
likely that our findings can be generalised to G6PD nor-
mal patients in many vivax-endemic regions, the vari-
ation in G6PD variants across different regions and the
disproportionate number of male patients in the current
study prevent the overall estimates of risk including pa-
tients with unknown G6PD status from being general-
ised globally. Finally, restriction of follow-up to a
maximum of 42 days prevented us from being able to es-
timate the overall haematological benefit beyond day 42
related to prevention of multiple future relapses as op-
posed to just the first relapse.
Conclusions
In summary, PQ administration in G6PD normal pa-
tients was not associated with a greater acute fall in Hb
compared to patients not treated with PQ. The reduc-
tion in Hb after treatment for vivax malaria was primar-
ily associated with the disease itself rather than
haemolysis due to PQ treatment. Indeed, within 42 days,
patients treated with PQ had better haematological out-
comes than those treated with chloroquine alone, con-
sistent with the prevention of further haematological
insults caused by recurrent parasitaemia. There was a
small but clinically relevant risk of severe Hb reduction
after treatment with PQ, even in patients with normal
G6PD status. Our results highlight the public health
benefits of radical cure for the treatment of P. vivax
when this can be offered in combination with accurate
point of care testing for G6PDd.
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Table S1. Studies included in the analysis. Table S2. Reasons for studies
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S2. Relationship between day 0 haemoglobin and percentage and
absolute change in haemoglobin on day 2/3. Table S10. Sensitivity
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days. Figure S4. Mean haemoglobin versus time profile for patients
with or without delayed parasite clearance. Table S14. Unadjusted
absolute and percentage change in haemoglobin and risk of anaemia
if G6PD deficient. References S1. Studies not included in the
analysis. (PDF 1347 kb)
Abbreviations
AOR: Adjusted odds ratio; CI: Confidence interval; CQ: Chloroquine;
G6PD: Glucose-6-phosphate dehydrogenase; G6PDd: Glucose-6-phosphate
dehydrogenase deficiency; Hb: Haemoglobin; IQR: Inter-quartile range;
PQ: Primaquine; PRISMA: Preferred Reporting Items for Systematic Reviews
and Meta-Analyses; PROSPERO: International Prospective Register of
Systematic Reviews; RBC: Red blood cells; SD: Standard deviation;
WWARN: WorldWide Antimalarial Resistance Network
Acknowledgements
We thank all patients and staff who participated in these clinical trials at all
the sites and the WWARN team for the technical and administrative support.
The findings and conclusions in this report are those of the author(s) and do
not necessarily represent the official position of the Centers for Disease
Control and Prevention.
Authors’ contributions
RJC, RNP, JAS, KT and ND conceived the study, analysed and interpreted the
data and drafted the manuscript. TA, SGA, AAn, NMA, AAse, AAss, GRA, BEB,
IB, CSC, UDA, AD, PJdV, AE, MSGM, MJG, JH, PAK, TK, WAK, MVGL, TL, BL, KL,
WMM, FN, DBP, GTP, APP, RNP, MR, KSa, AMS, WRJT, KT, GT, BQT, HTT, JLFV,
SW, NJW, TW and CJW conceived the individual studies, enrolled the
patients and undertook the individual studies. RJC, PD, PJG, CHS, KSt and JW
provided technical support, and RJC and PD undertook pooling of the
patient data. All authors revised the manuscript. All authors read and
approved the final manuscript.
Funding
RJC is supported by a Postgraduate Australian National Health and Medical
Research Council (NHMRC) Scholarship and a RACP NHMRC Kincaid-Smith
Scholarship. RNP is a Wellcome Trust Senior Fellow in Clinical Science
(200909). JAS is funded by an Australian NHMRC Senior Research Fellowship
1104975. KT is funded by the Bill and Melinda Gates Foundation
(OPP1164105 and OPP1054404). MVGL and WMM are research fellows sup-
ported by the Brazilian Council for Scientific and Technological Development
(CNPq). NJW is a Wellcome Trust Principal Fellow. NMA is funded by an Aus-
tralian NHMRC Senior Principal Research Fellowship (1135820). MJG is sup-
ported by an NHMRC Early Career Fellowship (1138860). PD is funded by
Tropical Network Fund, Nuffield Department of Clinical Medicine, University
of Oxford. WWARN is funded by Bill and Melinda Gates Foundation and
Exxon Mobil Foundation grants. This work was supported by the Australian
Centre for Research Excellence on Malaria Elimination (ACREME), funded by
the NHMRC of Australia (1134989). The funders of the study had no role in
the study design, data collection, data analysis, data interpretation or writing
of the paper. The corresponding authors had full access to all the data in the
study and had final responsibility for the decision to submit for publication.
Availability of data and materials
The data that support the findings of this study are available for access via
the WorldWide Antimalarial Resistance Network (WWARN.org). Requests for
access will be reviewed by a Data Access Committee to ensure that the use
of data protects the interests of the participants and researchers according
to the terms of ethics approval and principles of equitable data sharing.
Requests can be submitted by email to malariaDAC@iddo.org via the Data
Access Form available at WWARN.org/accessing-data. The WWARN is
registered with the Registry of Research Data Repositories (re3data.org).
Ethics approval and consent to participate
All data included in this analysis were obtained in accordance with ethical
approvals from the country of origin. The data are fully anonymised and
cannot be traced back to identifiable individuals. This systematic review did
not require separate ethical approval according to the guidelines of the
Oxford Central University Research Ethics Committee. The inclusion of
anonymised data from the US Centers for Disease Control and Prevention
underwent human subjects review and received non-research determination.
Consent for publication
Not applicable.
Competing interests
AAn reports grants from USAID Iniciativa Amazónica contra la Malaria/Red
Amazónica de la Vigilancia de las Drogas Antimaláricas AMI/RAVREDA and
personal fees from Pan American Health Organization PWR (BOL). NMA
reports grants from the Australian Government, National Health and Medical
Research Council. DBP reports grants from GSK outside the submitted work.
PJdV reports personal fees from ACE Pharma outside the submitted work. All
other authors declare that they have no competing interests.
Author details
1Global Health Division, Menzies School of Health Research and Charles
Darwin University, Darwin, Northern Territory, Australia. 2WorldWide
Antimalarial Resistance Network (WWARN), Clinical Module, Darwin, Northern
Territory, Australia. 3Centre for Epidemiology and Biostatistics, Melbourne
School of Population and Global Health, The University of Melbourne,
Melbourne, Victoria, Australia. 4Centre for Tropical Medicine and Global
Health, Nuffield Department of Clinical Medicine, University of Oxford,
Oxford, UK. 5Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine
Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot,
Thailand. 6ICAP, Columbia University Mailman School of Public Health, Addis
Ababa, Ethiopia. 7Addis Ababa University, Addis Ababa, Ethiopia. 8Armauer
Hansen Research Institute, Addis Ababa, Ethiopia. 9Departamento de Salud
Pública, Universidad de Barcelona, Barcelona, Spain. 10Organización
Panamericana de Salud, Oficina de País Bolivia, La Paz, Bolivia. 11Malaria and
Neglected Tropical Diseases Research Team, Bacterial, Parasitic, Zoonotic
Diseases Research Directorate, Ethiopian Public Health Institute, Addis Ababa,
Ethiopia. 12Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty
of Tropical Medicine, Mahidol University, Bangkok, Thailand. 13Nangarhar
Medical Faculty, Nangarhar University, Jalalabad, Afghanistan.
14Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia. 15Infectious
Diseases Society Sabah-Menzies School of Health Research Clinical Research
Unit, Kota Kinabalu, Sabah, Malaysia. 16Medicines for Malaria Venture, Geneva,
Switzerland. 17Medical Research Council Unit The Gambia at LSTMH, Fajara,
The Gambia. 18WorldWide Antimalarial Resistance Network (WWARN), Oxford,
UK. 19Institute of Drug Technology (Farmanguinhos), Oswaldo Cruz
Foundation (FIOCRUZ), Rio de Janeiro, Brazil. 20Vice-presidency of Research
and Reference Laboratories, Oswaldo Cruz Foundation (FIOCRUZ), Rio de
Janeiro, Brazil. 21Liverpool School of Tropical Medicine, Liverpool, UK.
22Department of Internal Medicine, Tergooi Hospital, Hilversum, the
Netherlands. 23Superintendência de Vigilância em Saúde do Estado do
Amapá - SVS/AP, Macapá, Amapá, Brazil. 24Universidade Federal do Amapá –
UNIFAP, Macapá, Amapá, Brazil. 25U.S. President’s Malaria Initiative, Malaria
Branch, U.S. Centers for Disease Control and Prevention, Atlanta, USA.
26Global Health Group, University of California San Francisco, San Francisco,
USA. 27Centre for Infection and Immunity Amsterdam (CINEMA), Division of
Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Centre,
Amsterdam, the Netherlands. 28Department of Biology, Addis Ababa
University, Addis Ababa, Ethiopia. 29Department of Biology, Jimma University,
Jimma, Ethiopia. 30International Centre for Diarrheal Diseases and Research,
Dhaka, Bangladesh. 31Fundação de Medicina Tropical Dr. Heitor Vieira
Dourado, Manaus, Brazil. 32Universidade do Estado do Amazonas, Manaus,
Brazil. 33Fundação Oswaldo Cruz, Instituto Leônidas e Maria Deane
(FIOCRUZ-Amazonas), Manaus, Brazil. 34Department of Infectious and Tropical
Diseases, London School of Hygiene and Tropical Medicine, London, UK.
35HealthNet-TPO, Kabul, Afghanistan. 36The Department of Pharmacology
and Therapy, Faculty of Medicine, Nusa Cendana University, Kupang,
Indonesia. 37Centro de Pesquisa em Medicina Tropical de Rondônia (CEPEM),
Porto Velho, Rondônia, Brazil. 38Universidade Federal de Rondônia (UNIR),
Porto Velho, Rondônia, Brazil. 39Division of Infectious Diseases, Tropical
Commons et al. BMC Medicine          (2019) 17:151 Page 11 of 13
Medicine and AIDS, Academic Medical Center, Amsterdam, the Netherlands.
40Tropical Diseases Clinical Research Center, Cho Ray Hospital, Ho Chi Minh
City, Vietnam. 41Department of Medicine, Kasturba Medical College, Manipal
Academy of Higher Education, Madhav Nagar, Manipal, Karnataka, India.
42Manipal McGill Center for Infectious Diseases, Manipal Academy of Higher
Education, Manipal, Karnataka, India. 43Department of Genome Sciences,
University of Washington, Seattle, USA. 44Programa de Pós-graduação em
Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Brazil.
45Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo
Cruz, Rio de Janeiro, Brazil. 46Oxford University Clinical Research Unit, Ho Chi
Minh City, Vietnam. 47Federal University of Pará (Universidade Federal do
Pará - UFPA), Belém, Pará, Brazil. 48Public Health Laboratory, Department of
Public Health, Ministry of Health, Thimphu, Bhutan. 49Gleneagles Hospital,
Kota Kinabalu, Sabah, Malaysia.
Received: 10 March 2019 Accepted: 9 July 2019
References
1. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, et al.
Multidrug-resistant Plasmodium vivax associated with severe and fatal
malaria: a prospective study in Papua. Indonesia PLoS Med. 2008;5(6):e128.
2. Genton B, D'Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, et al.
Plasmodium vivax and mixed infections are associated with severe malaria
in children: a prospective cohort study from Papua New Guinea. PLoS Med.
2008;5(6):e127.
3. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria:
neglected and not benign. Am J Trop Med Hyg. 2007;77(6 Suppl):79–87.
4. World Health Organization. World malaria report 2018. Geneva: World
Health Organization; 2018.
5. Douglas NM, Anstey NM, Buffet PA, Poespoprodjo JR, Yeo TW, White NJ, et
al. The anaemia of Plasmodium vivax malaria. Malar J. 2012;11:135.
6. Douglas NM, Lampah DA, Kenangalem E, Simpson JA, Poespoprodjo JR,
Sugiarto P, et al. Major burden of severe anemia from non-falciparum
malaria species in Southern Papua: a hospital-based surveillance study. PLoS
Med. 2013;10(12):e1001575.
7. Price RN, Douglas NM, Anstey NM, von Seidlein L. Plasmodium vivax
treatments: what are we looking for? Curr Opin Infect Dis. 2011;24(6):
578–85.
8. Tan KR, Hwang J. Tafenoquine receives regulatory approval in U.S. for
prophylaxis of malaria and radical cure of Plasmodium vivax. J Travel Med.
2018:25(1). https://doi.org/10.1093/jtm/tay071.
9. von Seidlein L, Auburn S, Espino F, Shanks D, Cheng Q, McCarthy J, et
al. Review of key knowledge gaps in glucose-6-phosphate
dehydrogenase deficiency detection with regard to the safe clinical
deployment of 8-aminoquinoline treatment regimens: a workshop
report. Malar J. 2013;12:112.
10. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency.
Lancet. 2008;371(9606):64–74.
11. Chu CS, Bancone G, Nosten F, White NJ, Luzzatto L. Primaquine-
induced haemolysis in females heterozygous for G6PD deficiency. Malar
J. 2018;17(1):101.
12. Thriemer K, Ley B, Bobogare A, Dysoley L, Alam MS, Pasaribu AP, et al.
Challenges for achieving safe and effective radical cure of Plasmodium vivax:
a round table discussion of the APMEN Vivax Working Group. Malar J. 2017;
16(1):141.
13. Recht J, Ashley E, White J. Safety of 8-aminoquinoline antimalarial medicines
Geneva, Switzerland: World Health Organization; 2014 [Available from: www.
who.int/malaria/publications/atoz/9789241506977/en/].
14. World Health Organisation. Guidelines for the treatment of malaria - 3rd
edition. Geneva: World Health Organization; 2015.
15. Commons RJ, Thriemer K, Humphreys G, Suay I, Sibley CH, Guerin PJ, et al.
The vivax surveyor: online mapping database for Plasmodium vivax clinical
trials. Int J Parasitol Drugs Drug Resist. 2017;7(2):181–90.
16. WorldWide Antimalarial Resistance Network. Data management and
statistical analysis plan v1.2 Oxford: WorldWide Antimalarial Resistance
Network; 2012 [Available from: www.wwarn.org/sites/default/files/
ClinicalDMSAP.pdf.]
17. Battle KE, Karhunen MS, Bhatt S, Gething PW, Howes RE, Golding N, et al.
Geographical variation in Plasmodium vivax relapse. Malar J. 2014;13:144.
18. Lee SJ, Stepniewska K, Anstey N, Ashley E, Barnes K, Binh TQ, et al. The
relationship between the haemoglobin concentration and the haematocrit
in Plasmodium falciparum malaria. Malar J. 2008;7:149.
19. WorldWide Antimalarial Resistance Network. Statistical analysis plan: WWARN
Vivax Haematology Study Group v0.2 Oxford: WorldWide Antimalarial
Resistance Network; 2016 [Available from: http://www.wwarn.org/sites/default/
files/attachments/documents/wwarn_sap_haematology_290117.pdf.]
20. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics.
1982;38(4):963–74.
21. Royston P, Altman DG. Regression using fractional polynomials of
continuous covariates: parsimonious parametric modelling (with discussion).
J R Stat Soc. 1994;43:429–67.
22. Royston P, Sauerbrei W. Multivariable model-building: a pragmatic approach
to regression analysis based on fractional polynomials for modelling
continuous variables. Chichester: Wiley; 2008.
23. Taylor WR, Widjaja H, Richie TL, Basri H, Ohrt C, Tjitra, et al. Chloroquine/
doxycycline combination versus chloroquine alone, and doxycycline alone for
the treatment of Plasmodium falciparum and Plasmodium vivax malaria in
northeastern Irian Jaya, Indonesia. Am J Trop Med Hyg. 2001;64(5–6):223–228.
24. Phan GT, de Vries PJ, Tran BQ, Le HQ, Nguyen NV, Nguyen TV, et al.
Artemisinin or chloroquine for blood stage Plasmodium vivax malaria in
Vietnam. Tropical Med Int Health. 2002;7(10):858–64.
25. Leslie T, Mayan MI, Hasan MA, Safi MH, Klinkenberg E, Whitty CJ, et al.
Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the
treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a
randomized controlled trial. JAMA. 2007;297(20):2201–9.
26. Ratcliff A, Siswantoro H, Kenangalem E, Wuwung M, Brockman A, Edstein
MD, et al. Therapeutic response of multidrug-resistant Plasmodium
falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in
southern Papua, Indonesia. Trans R Soc Trop Med Hyg. 2007;101(4):351–9.
27. Leslie T, Mayan I, Mohammed N, Erasmus P, Kolaczinski J, Whitty CJ, et al. A
randomised trial of an eight-week, once weekly primaquine regimen to
prevent relapse of Plasmodium vivax in Northwest Frontier Province.
Pakistan PLoS One. 2008;3(8):e2861.
28. Ketema T, Bacha K, Birhanu T, Petros B. Chloroquine-resistant Plasmodium
vivax malaria in Serbo town, Jimma zone, south-west Ethiopia. Malar J. 2009;
8:177.
29. Awab GR, Pukrittayakamee S, Imwong M, Dondorp AM, Woodrow CJ, Lee
SJ, et al. Dihydroartemisinin-piperaquine versus chloroquine to treat vivax
malaria in Afghanistan: an open randomized, non-inferiority, trial. Malar J.
2010;9:105.
30. Phyo AP, Lwin KM, Price RN, Ashley EA, Russell B, Sriprawat K, et al.
Dihydroartemisinin-piperaquine versus chloroquine in the treatment of
Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin
Infect Dis. 2011;53(10):977–84.
31. Poravuth Y, Socheat D, Rueangweerayut R, Uthaisin C, Pyae Phyo A, Valecha
N, et al. Pyronaridine-artesunate versus chloroquine in patients with acute
Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial.
PLoS One. 2011;6(1):e14501.
32. Barber BE, William T, Grigg MJ, Menon J, Auburn S, Marfurt J, et al. A
prospective comparative study of knowlesi, falciparum, and vivax malaria in
Sabah, Malaysia: high proportion with severe disease from Plasmodium
knowlesi and Plasmodium vivax but no mortality with early referral and
artesunate therapy. Clin Infect Dis. 2013;56(3):383–97.
33. Hwang J, Alemayehu BH, Reithinger R, Tekleyohannes SG, Takele T, Birhanu
SG, et al. In vivo efficacy of artemether-lumefantrine and chloroquine
against Plasmodium vivax: a randomized open label trial in central Ethiopia.
PLoS One. 2013;8(5):e63433.
34. Marques MM, Costa MR, Santana Filho FS, Vieira JL, Nascimento MT, Brasil
LW, et al. Plasmodium vivax chloroquine resistance and anemia in the
western Brazilian Amazon. Antimicrob Agents Chemother. 2014;58(1):342–7.
35. Anez A, Moscoso M, Laguna A, Garnica C, Melgar V, Cuba M, et al.
Resistance of infection by Plasmodium vivax to chloroquine in Bolivia. Malar
J. 2015;14:261.
36. Getachew S, Thriemer K, Auburn S, Abera A, Gadisa E, Aseffa A, et al.
Chloroquine efficacy for Plasmodium vivax malaria treatment in southern
Ethiopia. Malar J. 2015;14:525.
37. Gomes Mdo S, Vieira JL, Machado RL, Nacher M, Stefani A, Musset L, et al.
Efficacy in the treatment of malaria by Plasmodium vivax in Oiapoque, Brazil,
on the border with French Guiana: the importance of control over external
factors. Malar J. 2015;14:402.
Commons et al. BMC Medicine          (2019) 17:151 Page 12 of 13
38. Lidia K, Dwiprahasto I, Kristin E. Therapeutic effects of dyhidroartemisinin
piperaquine versus chloroquine for uncomplicated vivax malaria in Kupang,
East Nusa Tenggara, Indonesia. Int J Pharm Sci Rev Res. 2015;31(2):247–51.
39. Rishikesh K, Kamath A, Hande MH, Vidyasagar S, Acharya RV, Acharya V, et
al. Therapeutic assessment of chloroquine-primaquine combined regimen
in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in
southwestern India. Malar J. 2015;14:310.
40. Thanh PV, Hong NV, Van NV, Louisa M, Baird K, Xa NX, et al. Confirmed
Plasmodium vivax resistance to chloroquine in central Vietnam. Antimicrob
Agents Chemother. 2015;59(12):7411–9.
41. Grigg MJ, William T, Menon J, Barber BE, Wilkes CS, Rajahram GS, et al.
Efficacy of artesunate-mefloquine for chloroquine-resistant Plasmodium
vivax malaria in Malaysia: an open-label, randomized, controlled trial. Clin
Infect Dis. 2016;62(11):1403–11.
42. Ley B, Alam MS, Thriemer K, Hossain MS, Kibria MG, Auburn S, et al. G6PD
deficiency and antimalarial efficacy for uncomplicated malaria in
Bangladesh: a prospective observational study. PLoS One. 2016;11(4):
e0154015.
43. Pereira D, Daher A, Zanini G, Maia I, Fonseca L, Pitta L, et al. Safety, efficacy
and pharmacokinetic evaluations of a new coated chloroquine tablet in a
single-arm open-label non-comparative trial in Brazil: a step towards a user-
friendly malaria vivax treatment. Malar J. 2016;15:477.
44. Saravu K, Kumar R, Ashok H, Kundapura P, Kamath V, Kamath A, et al.
Therapeutic assessment of chloroquine-primaquine combined regimen in
adult cohort of Plasmodium vivax malaria from primary care centres in
southwestern India. PLoS One. 2016;11(6):e0157666.
45. Thuan PD, Ca NT, Van Toi P, Nhien NT, Thanh NV, Anh ND, et al. A
randomized comparison of chloroquine versus dihydroartemisinin-
piperaquine for the treatment of Plasmodium vivax infection in Vietnam. Am
J Trop Med Hyg. 2016;94(4):879–85.
46. Wangchuk S, Drukpa T, Penjor K, Peldon T, Dorjey Y, Dorji K, et al. Where
chloroquine still works: the genetic make-up and susceptibility of
Plasmodium vivax to chloroquine plus primaquine in Bhutan. Malar J. 2016;
15(1):277.
47. Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, et al.
Comparison of artemether-lumefantrine and chloroquine with and without
primaquine for the treatment of Plasmodium vivax infection in Ethiopia: a
randomized controlled trial. PLoS Med. 2017;14(5):e1002299.
48. Siqueira AM, Alencar AC, Melo GC, Magalhaes BL, Machado K, Alencar Filho
AC, et al. Fixed-dose artesunate-amodiaquine combination vs chloroquine
for treatment of uncomplicated blood stage P. vivax infection in the
Brazilian Amazon: an open-label randomized, controlled trial. Clin Infect Dis.
2017;64(2):166–74.
49. Chu CS, Phyo AP, Lwin KM, Win HH, San T, Aung AA, et al. Comparison of
the cumulative efficacy and safety of chloroquine, artesunate, and
chloroquine-primaquine in Plasmodium vivax malaria. Clin Infect Dis. 2018;
67(10):1543-9.
50. Grigg MJ, William T, Barber BE, Rajahram GS, Menon J, Schimann E, et al.
Age-related clinical spectrum of Plasmodium knowlesi malaria and predictors
of severity. Clin Infect Dis. 2018;67(3):350–9.
51. Chu CS, Phyo AP, Turner C, Win HH, Poe NP, Yotyingaphiram W, et al.
Chloroquine versus dihydroartemisinin-piperaquine with standard high-dose
primaquine given either for 7 days or 14 days in Plasmodium vivax malaria.
Clin Infect Dis. 2019:68(8):1311-9.
52. Pukrittayakamee S, Vanijanonta S, Chantra A, Clemens R, White NJ. Blood
stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. J
Infect Dis. 1994;169(4):932–5.
53. Commons RJ, Simpson JA, Thriemer K, Humphreys GS, Abreha T, Alemu SG,
et al. The effect of chloroquine dose and primaquine on Plasmodium vivax
recurrence: a WorldWide Antimalarial Resistance Network systematic review
and individual patient pooled meta-analysis. Lancet Infect Dis. 2018;18(9):
1025-34.
54. Luxemburger C, van Vugt M, Jonathan S, McGready R, Looareesuwan S,
White NJ, et al. Treatment of vivax malaria on the western border of
Thailand. Trans R Soc Trop Med Hyg. 1999;93(4):433–8.
55. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK,
Kochar SK, et al. Tafenoquine plus chloroquine for the treatment and
relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre,
double-blind, randomised, phase 2b dose-selection study. Lancet. 2014;
383(9922):1049–58.
56. Chu CS, Bancone G, Moore KA, Win HH, Thitipanawan N, Po C, et al.
Haemolysis in G6PD heterozygous females treated with primaquine for
Plasmodium vivax malaria: a nested cohort in a trial of radical curative
regimens. PLoS Med. 2017;14(2):e1002224.
57. Plewes K, Kingston HWF, Ghose A, Maude RJ, Herdman MT, Leopold SJ, et
al. Cell-free hemoglobin mediated oxidative stress is associated with acute
kidney injury and renal replacement therapy in severe falciparum malaria:
an observational study. BMC Infect Dis. 2017;17(1):313.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Commons et al. BMC Medicine          (2019) 17:151 Page 13 of 13
